Anticipation builds as DocGo prepares to announce a reduced Q2 loss; analysts fine-tune their predictions prior to the earnings call.

DCGO · DocGo Inc.

The AI's read

DocGo is due to report Q2 after the close Monday, with consensus showing a narrower loss (15c vs 21c) and revenue down year-over-year. The company also raised FY2026 sales guidance in May, which is the only clear positive in the text. The market has already sold the name, with shares down ~3% and RSI ~32, so some optimism may be priced out or being ignored. Analysts' recent price-target cuts suggest lingering skepticism despite the narrower loss view. Bottom line: we lean neutral. A modest beat could spark a short squeeze, but upside looks limited and the market reaction warns that expectations and positioning are mixed.